969,218 Shares in Rapport Therapeutics, Inc. $RAPP Acquired by Trv Gp Vi LLC

Trv Gp Vi LLC purchased a new stake in Rapport Therapeutics, Inc. (NASDAQ:RAPP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 969,218 shares of the company’s stock, valued at approximately $40,387,314,000. Rapport Therapeutics makes up about 17.4% of Trv Gp Vi LLC’s holdings, making the stock its 3rd biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in RAPP. Swedbank AB acquired a new stake in Rapport Therapeutics in the 4th quarter valued at approximately $3,434,000. Johnson & Johnson bought a new stake in Rapport Therapeutics during the second quarter worth $74,360,823,000. Dimensional Fund Advisors LP raised its holdings in shares of Rapport Therapeutics by 168.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company’s stock valued at $7,025,000 after purchasing an additional 141,011 shares during the period. Walleye Capital LLC bought a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $4,257,000. Finally, Goldman Sachs Group Inc. lifted its stake in Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after purchasing an additional 579,903 shares during the last quarter.

Rapport Therapeutics Stock Up 1.2%

Shares of Rapport Therapeutics stock opened at $49.01 on Wednesday. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -16.12 and a beta of 0.97. Rapport Therapeutics, Inc. has a 12-month low of $13.86 and a 12-month high of $49.50. The firm’s 50-day moving average price is $41.39 and its two-hundred day moving average price is $35.65.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, sell-side analysts expect that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of Rapport Therapeutics stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the transaction, the insider directly owned 6,280,525 shares of the company’s stock, valued at approximately $251,535,026.25. The trade was a 0.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the transaction, the chief executive officer directly owned 486,108 shares in the company, valued at approximately $23,338,045.08. This represents a 5.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 72,281 shares of company stock worth $3,269,892 over the last three months. Insiders own 12.48% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. UBS Group reissued a “strong-buy” rating on shares of Rapport Therapeutics in a research report on Monday. BTIG Research reiterated a “buy” rating and set a $65.00 target price on shares of Rapport Therapeutics in a research note on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and issued a $75.00 price target on shares of Rapport Therapeutics in a research note on Monday. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $62.86.

Rapport Therapeutics Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.